Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive status confers therapeutic sensitivity to Tamoxifen in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women.